Supreme Court Turns Down CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising fight with Natera, leaving a lower court ruling intact.
The U.S. Supreme Court has decided to sit this one out. The nation's highest court rejected CareDx's bid to appeal a false-advertising dispute involving genetic testing company Natera, meaning whatever the lower court decided is now the law of the land — at least for these two companies.
For the uninitiated, false-advertising cases between biotech rivals aren't exactly rare. Companies in the diagnostics space compete fiercely over which tests are more accurate, and marketing claims can cross legal lines pretty quickly. When CareDx and Natera locked horns, it set off a legal battle that eventually wound its way all the way up to the Supreme Court's doorstep — only to get turned away.
Read more Samson Mow Calls Bitcoin Bottom Amid Analyst Doubts →
When the Supreme Court declines to hear a case like this (a move called denying certiorari, if you want to sound smart at your next dinner party), it doesn't mean the justices weighed in on who was right or wrong. It simply means they chose not to take the case, and the previous ruling stands. That's a meaningful outcome for Natera, which can now move forward without the cloud of a high-court reversal hanging over it.
For investors keeping tabs on both NTRA and CareDx, Supreme Court rejections like this can shift sentiment quickly. Natera's position in the organ transplant diagnostics market — where its Prospera kidney transplant test competes directly with CareDx's products — remains a key battleground even with the legal chapter now largely closed. The competitive tension between these two isn't going anywhere just because the courtroom drama has cooled down.
Continue reading at Yahoo Finance.
